Mediar Therapeutics: Valuation, Funding & Investors
Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies designed to halt fibrosis by targeting the myofibroblast, the key pathogenic cell driving scarring and organ failure. The company advances antibody therapeutics across multiple organ systems with programs in systemic sclerosis, idiopathic pulmonary fibrosis, and chronic kidney disease.
Leadership & Board
- Current Number of Employees
- 60
- Current LinkedIn Followers
- 5,850
Latest Estimated Valuation
- Total Amount Raised
- $76M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $76M
- Latest Funding Round
- Series B
Company Momentum
PositiveMediar Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Mediar Therapeutics had 60 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Mediar Therapeutics had 5,850 followers as of November 2, 2026. The number of followers increased by 28 (0.48%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 07, 2026 | Series B | $76.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Longwood Fund | Series B |
| Amplitude Ventures | Series B |
| ICG | Series B |
| Asahi Kasei Pharma Ventures | Series B |
| Alexandria Real Estate Trust | Series B |
Similar Companies
A snapshot of private companies similar to Mediar Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
